Product Description
Chiauranib, a highly selective Aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor, was developed by Chipscreen Biosciences specifically to address drug resistance. (Sourced from: https://www.chipscreen.com/en/products/700.html)
Mechanisms of Action: VEGFR Inhibitor, PGFRa Inhibitor, AURK Inhibitor, CSF-1R Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Breakthrough Therapy - Small Cell Lung Cancer *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Akeso Pharm
Company Location: Asia Pacific
Company Founding Year: 2012
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China
Active Clinical Trial Count: 8
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Adenocarcinoma|Ovarian Cancer|Pancreatic Cancer|Pancreatic Ductal Carcinoma|Small Cell Lung Cancer
Phase 2: Sarcoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05505825 |
AK104-212 | P2 |
Completed |
Small Cell Lung Cancer |
2024-07-19 |
2025-03-13 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04921527 |
CHIPRO | P3 |
Recruiting |
Ovarian Cancer |
2024-12-31 |
2024-10-19 |
Patient Enrollment|Primary Endpoints |
|
NCT05497843 |
CAR204 | P2 |
Completed |
Sarcoma |
2025-01-03 |
2025-04-04 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT06492915 |
CAR205 | P2 |
Active, not recruiting |
Adenocarcinoma|Pancreatic Ductal Carcinoma|Pancreatic Cancer |
2026-05-31 |
12% |
2026-03-19 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT04830813 |
CHIS | P3 |
Completed |
Small Cell Lung Cancer |
2024-04-01 |
2024-12-10 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
CTR20221212 |
CTR20221212 | P2 |
Completed |
Sarcoma |
2025-01-03 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20242363 |
CTR20242363 | P2 |
Active, not recruiting |
Adenocarcinoma|Pancreatic Cancer|Pancreatic Ductal Carcinoma |
None |
2026-10-18 |
Patient Enrollment|Treatments|Trial Status |
|
NCT07445295 |
CAR304 | P3 |
Not yet recruiting |
Pancreatic Cancer|Pancreatic Ductal Carcinoma|Adenocarcinoma |
2028-06-30 |
13% |
2026-03-04 |